Information  X 
Enter a valid email address

Byotrol PLC (BYOT)

  Print          Annual reports

Monday 07 September, 2020

Byotrol PLC

Grant Award

RNS Number : 1222Y
Byotrol PLC
07 September 2020
 

 

 

B y otrol Plc

( " B y o t rol" or the "Group")

 

Award of £350k grant to investigate anti-viral properties of seaweed

 

 

 

 

Byotrol plc (AIM:BYOT), the specialist infection prevention and control company, is pleased to announce that it has secured a significant grant from Innovate UK to further investigate the anti-viral properties of certain common forms of seaweed.

 

The total award is £350k over 16 months, of which £108k will be paid to Byotrol's academic partner, the Molecular Virology Research Group at the University of Liverpool, led by Professor James Stewart. The grant is specifically for research into seaweeds in sanitising products, but we believe the resulting discoveries will have significance outside of Byotrol's core markets, including potentially animal feedstuffs.

 

This grant award will help Byotrol build further on its research and development programme into developing biocides from sustainable sources.  This programme, which Byotrol has been exploring for many years has demonstrated high potency anti-viral action from extracts from commonly-occurring seaweeds, the results of which have already supported a new patent filing by the Group.  Byotrol expects to file further patents as the programme develops.

 

 

 

 

Trevor Francis, Chief Technology Officer of Byotrol plc commented :

 

We are delighted that Innovate UK is supporting our research into the anti-viral properties of seaweeds and we are very pleased to be working on this project with Professor James Stewart's excellent team at the University of Liverpool.  It is a very exciting area of development for Byotrol.

 

 

 

 

Enquiries:

 

Byotrol plc 

Trevor Francis - Chief Technology Officer

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer  01925 742 000

 

finnCap

Geoff Nash/Kate Bannatyne - Corporate Finance  020 7220 0500

Richard Chambers - ECM

 

Flagstaff Strategic and Investor Communications

Tim Thompson/Andrea Seymour/Fergus Mellon                            +44 (0)207 129 1474

[email protected]

 

 

 

This announcement is released by Byotrol plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKKQBQQBKDBCK

a d v e r t i s e m e n t